EPO and hydrops fetalis: SGLT2 inhibitors benefit HF patients (HFrEF, HFmrEF, and HFpEF) most probably due to diuresis, improved cardiomyocyte metabolism, increased erythropoietin (EPO) release, and modifications in cardiac ion channels.